Mirvetuximab soravtansine

November 17, 2020November 17, 2020

ImmunoGen Teams Up With Huadong Medicine to Develop Mirvetuximab in China

News

ImmunoGen has announced a collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co, a subsidiary of Huadong Medicine, to develop and commercialize the ovarian cancer treatment mirvetuximab soravtansine to patients in China, ... Read more

June 18, 2020June 18, 2020

Mirvetuximab Soravtansine-Avastin Combo Linked to Promising Responses

News

When given alongside Avastin (bevacizumab), mirvetuximab soravtansine leads to promising treatment responses in women with recurrent ovarian cancer — particularly those whose tumors contain high levels of the protein folate ... Read more

December 17, 2019January 21, 2020

Pivotal Trial of Mirvetuximab Soravtansine in Advanced Ovarian Cancer Levels Likely in 2020

News

ImmunoGen is planning to open an open-label, pivotal clinical trial of mirvetuximab soravtansine in platinum-resistant ovarian cancer patients with high levels of the folate receptor alpha (FRα) protein early next year, ... Read more

October 7, 2019October 7, 2019

Mirvetuximab Soravtansine Effectively Delays Disease Progression in FRα-high Ovarian Cancers, Analysis Finds

News

ImmunoGen’s investigational therapy mirvetuximab soravtansine effectively delays disease progression in women with ovarian cancer who have high levels of the folate receptor alpha (FRα) protein, compared with chemotherapy, according to ... Read more

May 22, 2019

Mirvetuximab Combos for Platinum-resistant Ovarian Cancer Showing Promise in Trial Updates

News

Combining Immunogen‘s mirvetuximab soravtansine, an investigational antibody-drug conjugate, with Avastin (bevacizumab) showed signs of favorable efficacy and demonstrated a manageable safety profile in patients with platinum-resistant ovarian cancer, according to ... Read more

March 11, 2019

Mirvetuximab Soravtansine Fails to Delay Disease Progression in FRα-positive Ovarian Cancers, Trial Shows

News

Mirvetuximab soravtansine, an investigational antibody-drug conjugate targeting the folate receptor alpha (FRα) protein, was no better than chemotherapy at delaying disease progression or death in ovarian cancer patients included in ... Read more

June 27, 2018

Mirvetuximab Soravtansine Given FDA Fast Track Designation for Ovarian Cancer Treatment

News

Mirvetuximab soravtansine (IMGN853), an investigational antibody-drug conjugate, has been granted fast track designation by the U.S. Food and Drug Administration for the treatment of ovarian cancer patients, ImmunoGen, the therapy’s maker, announced. The ... Read more

May 25, 2018May 25, 2018

Mirvetuximab Soravtansine Combo Therapies Show Promise for Ovarian Cancer, Clinical Trial Shows

News

Combinations of mirvetuximab soravtansine (IMGN853) with either Avastin (bevacizumab) or Paraplatin (carboplatin) are showing promise in certain ovarian cancer patients, particularly those who received multiple prior lines of therapy, the investigational therapy’s developer, ImmunoGen, recently announced. ... Read more

May 7, 2018

Phase 3 Trial of Mirvetuximab Soravtansine in Ovarian Cancer OK’d to Continue as Planned

News

A Phase 3 trial evaluating ImmunoGen’s mirvetuximab soravtansine (IMGN853) in platinum-resistant ovarian cancer patients is on its way to achieving its objectives, an interim futility analysis shows. As a result, the FORWARD ... Read more

May 22, 2017

ImmunoGen’s Investigative Therapy for Ovarian Cancer Shows Potential in Clinical Studies

News

ImmunoGen will show promising safety and efficacy data of its investigative treatment mirvetuximab soravtansine for the treatment of FRα-positive epithelial ovarian cancer (EOC). The positive top-line data will be presented in three poster ... Read more